A prospective study of diagnosis biomarkers of esophageal squamous cell carcinoma

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000031507

Enrollment

Unknown

Registered

2020-04-03

Start date

2015-06-18

Completion date

Unknown

Last updated

2020-04-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal squamous cell carcinoma

Interventions

Gold Standard:esophageal biopsy pathology

Index test:biomarker

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Volunteer to participate in the study and sign the informed consent form; 2. Aged from 18 to 75 years old; 3. Esophageal cancer: the patients with esophageal squamous cell carcinoma who have the possibility of resection or only chemoradiotherapy, controls: the participants without esophageal cancer.

Exclusion criteria

Exclusion criteria: 1. Patients with hepatic and renal insufficiency: AST and ALT exceeding 3 times of the normal upper limit and CCR 170/110mmHg); 7. Infectious diseases such as hepatitis A, hepatitis B, AIDS, tuberculosis or desmosis are in active stage; 8. Severe infections, especially those in the lungs; 9. Patients concurrent with severe oral disease (severe periodontitis and oral tumors, etc.); 10. Didn't have the ability of being informed the consent; 11. Patients who have participated in other clinical trials within one year prior or are participating in other clinical trials.

Design outcomes

Primary

Measure	Time frame
mRNA;LncRNA;miRNA;piRNA;chimeric RNA;	—

Secondary

Measure	Time frame
Disease-free survival;Relapse-free survival;Overall survival;	—

Countries

China

Contacts

Public ContactHao Zhang

Ji'nan University

haolabcancercenter@163.com+86 13502953989

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026